Skip to main content
Premium Trial:

Request an Annual Quote

Consistency May Be a Hobgoblin, But We Appreciate It Anyway

Daniel MacArthur at Genetic Future blogs about an Australian company called Genetic Technologies that appears to be reneging on a promise to allow other screening labs to test for BRCA1 and BRCA2, for which it won exclusive testing rights in Australia and New Zealand five years ago. Earlier this month, MacArthur says, "familial cancer screening laboratories around Australia and New Zealand received letters from the company ordering that they cease offering the tests within seven days. ... The concern, of course, is that this move will grant a complete monopoly to Genetic Technologies as the sole testing facility in the region, driving prices up." MacArthur posits that the move may be an attempt to shore up the company's falling stock price.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.